November 2, 2015 — After spending the past six years scavenging for lab equipment and operating on a shoestring, San Diego’s Crinetics Pharmaceuticals has finally landed its first round of institutional funding. The startup, which is developing new oral drugs for treating an array of endocrine disorders, said today it has raised a $40 million Series A financing led by 5AM Ventures, Versant Ventures, and Vivo Capital. Read the full article here.